Form 8-K - Current report:
SEC Accession No. 0001193125-23-219580
Filing Date
2023-08-24
Accepted
2023-08-24 08:09:00
Documents
14
Period of Report
2023-08-24
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d454718d8k.htm   iXBRL 8-K 25075
2 EX-99.1 d454718dex991.htm EX-99.1 11915
6 GRAPHIC g454718dsp1a.jpg GRAPHIC 11186
  Complete submission text file 0001193125-23-219580.txt   177068

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tsha-20230824.xsd EX-101.SCH 2844
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20230824_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20230824_pre.xml EX-101.PRE 11703
8 EXTRACTED XBRL INSTANCE DOCUMENT d454718d8k_htm.xml XML 3468
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 231198943
SIC: 2836 Biological Products, (No Diagnostic Substances)